Medical device company, Hyperfine, Inc. (Nasdaq: HYPR) has announced the launch of the eighth generation of its AI-powered Swoop® system software. The latest software has…
January 10, 2024
Biopharmaceutical company, Ambrx (Nasdaq: AMAM), has announced it will be acquired by Johnson & Johnson for $28.00 per share in cash, for a total equity…
January 02, 2024
Better Therapeutics Targets FDA Breakthrough Device Designation for Liver Disease Treatment
Prescription digital therapeutics (PDTs) pioneer, Better Therapeutics (Nasdaq: BTTX), has submitted a request to the FDA for Breakthrough Device Designation for its novel PDT designed…
December 20, 2023
First Dosing in Clinical Trial to Trigger $10M Payment for Compugen; Share Price Skyrockets 170%
Cancer immunotherapy company, Compugen Ltd (Nasdaq: CGEN) will be eligible to receive a milestone payment of $10 million from AstraZeneca (Nasdaq: AZN) when the first…
BioStem Technologies (OTC: BSEM) has strengthened its Board of Directors this week with the appointment of industry veterans, Mr. Thomas Dugan as Chairman and Mr….
December 13, 2023
FDA Grants PMA Supplement Approval for ReShape Lifesciences Lap Band; Shares Surge 100%
ReShape Lifesciences (Nasdaq: RSLS) has been granted FDA approval of a PMA supplement for the company’s next generation, enhanced Lap-Band® 2.0 FLEX. The company’s share…
December 12, 2023
Anixa Advances Breast Cancer Vaccine
Anixa Biosciences, Inc. (Nasdaq: ANIX) has reported positive results from a Phase 1 clinical trial of its breast cancer vaccine for Triple Negative breast cancer…
SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) has announced positive initial topline data from its ongoing Phase 2a clinical trial of its novel and highly…
Vistagen Therapeutics (Nasdaq: VTGN) has announced the pricing of a $100 million underwritten offering of its common stock and warrants. Vistagen intends to use the…
October 02, 2023
Next-Gen Bipolar Disorder Treatment Progressing, Says Alzamend
Clinical stage biopharmaceutical company, Alzamend Neuro (Nasdaq: ALZN), has received a “Study May Proceed” letter from the FDA for a Phase IIA clinical study of…